Maxim Group Analysts Give IntelliPharmaCeutics Intl (IPCI) a $2.00 Price Target

IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) received a $2.00 price target from analysts at Maxim Group in a research note issued on Friday. The brokerage currently has a “buy” rating on the stock. Maxim Group’s price objective would indicate a potential upside of 166.70% from the stock’s current price.

A number of other equities analysts have also issued reports on the stock. HC Wainwright began coverage on shares of IntelliPharmaCeutics Intl in a research report on Friday, January 19th. They set a “buy” rating and a $2.50 target price on the stock. Zacks Investment Research lowered shares of IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a research report on Wednesday, January 17th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $2.40.

Shares of IntelliPharmaCeutics Intl (IPCI) traded up $0.01 during trading on Friday, hitting $0.75. 213,919 shares of the stock were exchanged, compared to its average volume of 548,486. IntelliPharmaCeutics Intl has a twelve month low of $0.70 and a twelve month high of $2.92. The firm has a market capitalization of $26.03, a PE ratio of -2.21 and a beta of 1.06.

An institutional investor recently raised its position in IntelliPharmaCeutics Intl stock. Advisor Group Inc. increased its stake in shares of IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) by 57.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,409 shares of the company’s stock after acquiring an additional 17,342 shares during the quarter. Advisor Group Inc. owned about 0.16% of IntelliPharmaCeutics Intl worth $100,000 at the end of the most recent reporting period. 3.28% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Maxim Group Analysts Give IntelliPharmaCeutics Intl (IPCI) a $2.00 Price Target” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/09/maxim-group-analysts-give-intellipharmaceutics-intl-ipci-a-2-00-price-target.html.

IntelliPharmaCeutics Intl Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply